These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23610115)

  • 21. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
    Prescrire Int; 2016 Feb; 25(168):37. PubMed ID: 27042725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
    Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib-Sunitinib Sequence: The Jury Is Out.
    Albiges L; Escudier B
    Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
    [No Abstract]   [Full Text] [Related]  

  • 24. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
    Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
    Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
    [No Abstract]   [Full Text] [Related]  

  • 25. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
    Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
    Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
    Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
    Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
    Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib-induced tuberculosis reactivation.
    Teo M; O'Connor TM; O'Reilly SP; Power DG
    Onkologie; 2012; 35(9):514-6. PubMed ID: 23007150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
    Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
    Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
    Bellesoeur A; Carton E; Mir O; Groussin L; Blanchet B; Billemont B; Clerc J; Goldwasser F
    Invest New Drugs; 2014 Jun; 32(3):569-72. PubMed ID: 24399106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
    Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
    [No Abstract]   [Full Text] [Related]  

  • 32. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 33. Sorafenib: osteonecrosis of the jaw.
    Prescrire Int; 2015 Nov; 24(165):269. PubMed ID: 26688904
    [No Abstract]   [Full Text] [Related]  

  • 34. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 35. Psychotic disorder induced by a combination of sorafenib and BAY86-9766.
    Kuo YL; Yang YK; Cheng HC; Yen CJ; Chen PS
    Gen Hosp Psychiatry; 2014; 36(4):450.e5-7. PubMed ID: 24773940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
    Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
    J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
    [No Abstract]   [Full Text] [Related]  

  • 37. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
    Chevreau C; Le Cesne A; Ray-Coquard I; Italiano A; Cioffi A; Isambert N; Robin YM; Fournier C; Clisant S; Chaigneau L; Bay JO; Bompas E; Gauthier E; Blay JY; Penel N
    Cancer; 2013 Jul; 119(14):2639-44. PubMed ID: 23589078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Side effects of sorafenib and countermeasures].
    Nakayama M; Arai Y; Nishimura K
    Hinyokika Kiyo; 2012 Nov; 58(11):635-7. PubMed ID: 23254792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
    Okada K; Nakano Y; Yamasaki K; Nitani C; Fujisaki H; Hara J
    Cancer Med; 2016 Aug; 5(8):1947-9. PubMed ID: 27264843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
    Hioki T; Takama H; Makita S; Chen KR; Watanabe D; Akiyama M
    Eur J Dermatol; 2017 Oct; 27(5):546-547. PubMed ID: 29084643
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.